Cerevance Achieves Key Endpoints in Phase... - Cure Parkinson's
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN42
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
145 trials are registered and ongoing clinical trials for therapeutics targeting PD, of which 51...
Cure Parkinson’s and Van Andel Institute announce funding for a phase 1 clinical trial of low-dose lithium in Parkinson’s disease
Cure Parkinson’s and Van Andel Institute announce funding for a phase 1 clinical trial of...
MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment
New technology that uses MRI-guided focused ultrasound to target areas of the brain affected by...
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial
sounds promising what do you think?...
Clinical trial suggests Parkinson's drug is safe in humans
A new study finds an experimental drug that is significant for PD treatment " A large team of...
Related Posts
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease- Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
Nilotinib Does Not Show Promise for Benefit in Phase II Nilotinib for Parkinson’s Disease (NILO-PD) Trial
